What is the mechanism of action of dutasteride?

Mechanism of Action of Dutasteride

Dutasteride is a competitive and specific inhibitor of both type 1 and type 2 isoforms of 5-alpha-reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT), forming an extremely stable enzyme complex with dissociation that is extremely slow under both in vitro and in vivo conditions. 1

Enzymatic Inhibition Profile

• Dutasteride blocks both type 1 and type 2 5-alpha-reductase isoenzymes, distinguishing it from finasteride which primarily inhibits only type 2. 1
• The type 2 isoenzyme is primarily active in reproductive tissues (prostate, seminal vesicles), while the type 1 isoenzyme is responsible for testosterone conversion in the skin and liver. 1
• This dual inhibition results in more complete suppression of DHT production throughout the body compared to selective type 2 inhibition alone. 2

Pharmacodynamic Effects on Hormones

• After 1-2 weeks of dutasteride 0.5 mg daily, median serum DHT concentrations are reduced by 85-90%, with maximum effect observed within this timeframe. 1
• Long-term treatment achieves even greater suppression: median DHT reduction reaches 94% at 1 year, 93% at 2 years, and 95% at both 3 and 4 years. 1
• Serum testosterone increases modestly (median 19-26%) but remains within the physiologic range, as the blocked conversion pathway results in testosterone accumulation. 1
• In prostatic tissue specifically, dutasteride reduces mean DHT concentrations from 5,793 pg/g (placebo) to 784 pg/g, while increasing tissue testosterone from 93 pg/g to 2,073 pg/g. 1

Receptor Binding and Specificity

• Dutasteride does not bind to the human androgen receptor, meaning its effects are purely enzymatic rather than receptor-mediated. 1
• The drug forms a stable enzyme complex with 5-alpha-reductase through competitive inhibition, and dissociation from this complex is extremely slow. 1

Clinical Relevance of DHT Suppression

• DHT is the androgen primarily responsible for initial development and subsequent enlargement of the prostate gland, making its suppression therapeutically relevant for benign prostatic hyperplasia. 1
• In androgenetic alopecia, DHT miniaturizes hair follicles in genetically susceptible individuals, and its suppression allows follicle recovery. 2
• Males with genetically inherited type 2 5-alpha-reductase deficiency have decreased DHT levels throughout life, maintain small prostate glands, and do not develop BPH, demonstrating the physiologic importance of this pathway. 1

Effects on Other Hormonal Parameters

• Dutasteride causes no clinically significant changes in sex hormone-binding globulin, estradiol, luteinizing hormone, follicle-stimulating hormone, free thyroxine (T4), or dehydroepiandrosterone after 52 weeks of treatment. 1
• A statistically significant but clinically modest increase in thyroid-stimulating hormone (0.4 mcIU/mL, 12.4% median change) occurs at 52 weeks, which returns to baseline within 24 weeks of discontinuation. 1